News Center
——
News Center
BroadenBio Announces First Patient Dosed in Phase 1 Study of BB102 in China
Time of issue：
2023-01-05
Author:
BroadenBio
Origin:
BroadenBio
On Jan. 5th 2023, BroadenBio Co., Ltd. (BroadenBio) announced the first patient enrollment and dosed in the Phase 1 clinical trial of the independently developed, highly-selective small molecule inhibitor BB102 in Henan Cancer Hospital, marking the substantive progress of the clinical trial for this program. The Phase 1 clinical trial of BB102 is led by renowned medical expert Professor Luo Suxia as the principal investigator.
The Phase 1 clinical trial will assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of the oral small molecule Fibroblast Growth Factor Receptor 4 (FGFR4) BB102 in adults with advanced solid tumors. Currently, no drug with the same target has been approved for marketing globally.
BB102 is an innovative, highly-selective, reversible covalent FGFR4 inhibitor, which has shown significant anti-tumor efficacy in a variety of mice tumor models in preclinical studies. Based on the novel mechanism and extensive translational medicine studies, BB102 will be investigated for the treatment of advanced solid tumors with FGFR4/FGF19 high expression or FGFR4 mutation. Besides, BB102 is expected to have lesser adverse effects in clinical trials, since no obvious off-target toxicity has been observed in animal studies.
"The successful administration of BB102 for the first patient is another milestone for BroadenBio. I would like to express my heartfelt thanks to the team of Professor Luo Suxia from Henan Cancer Hospital, the team of Professor Guo Yabing from Nanfang Hospital of Southern Medical University, The company's shareholders and other people for their full support, and I am also grateful to the company's team for their hard work," said Xingmin Zhang, M.D., Ph.D., founder and Chief Executive Officer of BroadenBio. "In the New Year, we look forward to proceeding the clinical research of BB102 efficiently with the joint efforts of everyone, accelerating the progress of the other two preclinical projects into the clinic, and benefiting more cancer patients."
address：
A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176
phone：
Copyright ©2019 BroadenBio